FCMV
KNTE

Foresite Capital Management V’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Foresite Capital Management V’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,525,957
Closed -$9.38M – 7
2024
Q1 		$9.38M Hold
3,525,957
– – 8.8% 4
2023
Q4 		$8.36M Hold
3,525,957
– – 11.39% 4
2023
Q3 		$4.94M Hold
3,525,957
– – 7.88% 5
2023
Q2 		$10.7M Buy
3,525,957
+1,550,956
+79% +$5.98M 7.8% 6
2023
Q1 		$12.3M Buy
1,975,001
+1,100,000
+126% +$6.7M 9.13% 4
2022
Q4 		$5.34M Hold
875,001
– – 4.15% 7
2022
Q3 		$10.5M Hold
875,001
– – 8.04% 5
2022
Q2 		$11M Hold
875,001
– – 7.71% 7
2022
Q1 		$9.85M Hold
875,001
– – 4.02% 9
2021
Q4 		$15.5M Hold
875,001
– – 3.81% 8
2021
Q3 		$20.1M Hold
875,001
– – 6.26% 5
2021
Q2 		$20.4M Hold
875,001
– – 8.01% 4
2021
Q1 		$27.3M Hold
875,001
– – 8.02% 4
2020
Q4 		$34.8M Buy
+875,001
New +$35.1M 25.78% 1

Foresite Capital Management V's KNTE Position: Q2 2024 in Review

Foresite Capital Management V sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 3,525,957 shares — an estimated $9.38M sold.

Foresite Capital Management V first reported a position in KNTE in Q4 2020 and held it in 14 quarters. The position peaked at $34.8M in Q4 2020. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

  • Foresite Capital Management V reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Foresite Capital Management V sold 3,525,957 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $9.38M.
  • Foresite Capital Management V first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 14 quarters.
  • Foresite Capital Management V's Kinnate Biopharma Inc. Common Stock position peaked at $34.8M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Foresite Capital Management V's 13F filing for Q2 2024, filed 13 Aug 2024.